RT Journal Article
SR Electronic
T1 Swiss public health measures associated with reduced SARS-CoV-2 transmission using genome data
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.11.11.21266107
DO 10.1101/2021.11.11.21266107
A1 Nadeau, Sarah A.
A1 Vaughan, Timothy G.
A1 Beckmann, Christiane
A1 Topolsky, Ivan
A1 Chen, Chaoran
A1 Hodcroft, Emma
A1 Schär, Tobias
A1 Nissen, Ina
A1 Santacroce, Natascha
A1 Burcklen, Elodie
A1 Ferreira, Pedro
A1 Jablonski, Kim Philipp
A1 Posada-Céspedes, Susana
A1 Capece, Vincenzo
A1 Seidel, Sophie
A1 de Souza, Noemi Santamaria
A1 Martinez-Gomez, Julia M.
A1 Cheng, Phil
A1 Bosshard, Philipp P.
A1 Levesque, Mitchell P.
A1 Kufner, Verena
A1 Schmutz, Stefan
A1 Zaheri, Maryam
A1 Huber, Michael
A1 Trkola, Alexandra
A1 Cordey, Samuel
A1 Laubscher, Florian
A1 Gonçalves, Ana Rita
A1 Aeby, Sébastien
A1 Pillonel, Trestan
A1 Jacot, Damien
A1 Bertelli, Claire
A1 Greub, Gilbert
A1 Leuzinger, Karoline
A1 Stange, Madlen
A1 Mari, Alfredo
A1 Roloff, Tim
A1 Seth-Smith, Helena
A1 Hirsch, Hans H.
A1 Egli, Adrian
A1 Redondo, Maurice
A1 Kobel, Olivier
A1 Noppen, Christoph
A1 du Plessis, Louis
A1 Beerenwinkel, Niko
A1 Neher, Richard A.
A1 Beisel, Christian
A1 Stadler, Tanja
YR 2022
UL http://medrxiv.org/content/early/2022/08/22/2021.11.11.21266107.abstract
AB Genome sequences from evolving infectious pathogens allow quantification of case introductions and local transmission dynamics. We sequenced 11,357 SARS-CoV-2 genomes from Switzerland in 2020 - the 6th largest effort globally. Using a representative subset of these data, we estimated viral introductions to Switzerland and their persistence over the course of 2020. We contrast these estimates with simple null models representing the absence of certain public health measures. We show that Switzerland’s border closures de-coupled case introductions from incidence in neighboring countries. Under a simple model, we estimate an 86 - 98% reduction in introductions during Switzerland’s strictest border closures. Furthermore, the Swiss 2020 partial lockdown roughly halved the time for sampled introductions to die out. Finally, we quantified local transmission dynamics once introductions into Switzerland occurred, using a novel phylodynamic model. We find that transmission slowed 35 – 63% upon outbreak detection in summer 2020, but not in fall. This finding may indicate successful contact tracing over summer before overburdening in fall. The study highlights the added value of genome sequencing data for understanding transmission dynamics.One Sentence Summary Phylogenetic and phylodynamic methods quantify the drop in case introductions and local transmission with implementation of public health measures.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the Swiss National Science Foundation grant 31CA30_196267 (to TS) and ETH Zurich.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study involves only openly available pathogen genome sequence data collected from humans, which can be obtained from GISAID at gisaid.org. The Ethikkommission Nordwest- und Zentralschweiz (EKNZ) ruled on the ethics of genome sequence generation by the Swiss SARS-CoV-2 Sequencing Consortium (S3C) for this research. Ethical approval was waived as only viral material is processed.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll genome sequence data used in the analysis is available on GISAID (https://www.gisaid.org/). Data generated by the Swiss SARS-CoV-2 Sequencing Consortium is available on GISAID (submitting lab: Department of Biosystems Science and Engineering, ETH Zuerich). The code used to generate figures and values for the manuscript is available at https://github.com/SarahNadeau/cov-swiss-phylo. The phylogenetic analysis code is at https://github.com/cevo-public/Grapevine-SARS-CoV-2-Introduction-Analysis and the phylodynamic analysis code, including BEAST2 XML files, is at https://github.com/tgvaughan/TransmissionChainAnalyses.